A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT ID: NCT06624228
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
684 participants
INTERVENTIONAL
2024-10-21
2026-05-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bimekizumab
Study participants will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding during treatment period.
Bimekizumab
Study participants will receive bimekizumab at pre-specified time points.
Placebo
Study participants will receive placebo at pre-specified time points.
Risankizumab
Study participants will receive assigned risankizumab dosage regimen and placebo to maintain the blinding during treatment period.
Risankizumab
Study participants will receive risankizumab at pre-specified time points.
Placebo
Study participants will receive placebo at pre-specified time points.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bimekizumab
Study participants will receive bimekizumab at pre-specified time points.
Risankizumab
Study participants will receive risankizumab at pre-specified time points.
Placebo
Study participants will receive placebo at pre-specified time points.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Study participant must have at least 1 active psoriatic lesion(s) and/or a documented history of chronic plaque-type psoriasis (PSO).
* Study participants may currently be on conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy and must have previously been treated with at least 1 csDMARD (methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ)). Study participants must have had an inadequate response to therapy or discontinued due to intolerance. (Inadequate response is determined by the Investigator and is defined as not achieving the minimal response after 12 weeks of therapy.)
* Study participants can either be biological disease-modifying antirheumatic drug (bDMARD)-naïve or have received not more than 1 prior tumor necrosis factor alpha (TNFα) inhibitor. Study participants who have been on a TNFα inhibitor previously must not have discontinued the TNFα inhibitor due to financial or health insurance reasons and must have either:
* experienced an inadequate response to previous treatment given at an approved dose for at least 3 months, or
* been intolerant to administration (eg, had a side-effect/adverse event (AE) that led to discontinuation).
* Study participant is taking or has taken prohibited PsA or PSO medications without meeting the mandatory wash-out period relative to the Baseline Visit.
* Study participant is taking or has taken janus kinase (JAK) inhibitor.
* Study participant is taking or has taken bDMARDs, including bimekizumab or risankizumab, with the exception of having received 1 prior TNFα inhibitor.
* Study participant previously participated in another study of a medical device under investigation within the 4 weeks prior to the Screening Visit or is currently participating in another study of a medical device under investigation.
Exclusion Criteria
* Female participants who are breastfeeding, pregnant, or plan to become pregnant during the study.
* Participant has an active infection or a history of recent serious infections.
* Participant has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection.
* Study participant has a diagnosis of inflammatory conditions other than PSO or PsA including, but not limited to, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, reactive arthritis, and axial spondyloarthritis.
* Study participants with a history of anterior uveitis are allowed if they have no active symptoms at Screening or Baseline. Study participants with a diagnosis of Crohn's disease or ulcerative colitis are allowed if they have no active symptomatic disease at Screening or Baseline.
* Study participants with fibromyalgia or osteoarthritis symptoms that in the Investigator's opinion would have potential to interfere with efficacy assessments.
* Participant has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer.
* Participant has a history of chronic alcohol or drug abuse within 6 months prior to Screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Biopharma SRL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pa0016 50662
Gilbert, Arizona, United States
Pa0016 50062
Glendale, Arizona, United States
Pa0016 50058
Phoenix, Arizona, United States
Pa0016 50131
Sun City, Arizona, United States
Pa0016 50654
Covina, California, United States
Pa0016 50301
La Jolla, California, United States
Pa0016 50663
San Diego, California, United States
Pa0016 50672
Santa Monica, California, United States
Pa0016 50239
Brandon, Florida, United States
Pa0016 50630
Clearwater, Florida, United States
Pa0016 50679
Cutler Bay, Florida, United States
Pa0016 50685
Fort Lauderdale, Florida, United States
Pa0016 50059
Ormond Beach, Florida, United States
Pa0016 50324
Plantation, Florida, United States
Pa0016 50678
Zephyrhills, Florida, United States
Pa0016 50651
Skokie, Illinois, United States
Pa0016 50650
Willowbrook, Illinois, United States
Pa0016 50686
Hagerstown, Maryland, United States
Pa0016 50665
Lansing, Michigan, United States
Pa0016 50551
Saint Clair Shores, Michigan, United States
Pa0016 50689
Eagan, Minnesota, United States
Pa0016 50682
Kansas City, Missouri, United States
Pa0016 50016
St Louis, Missouri, United States
Pa0016 50653
Albuquerque, New Mexico, United States
Pa0016 50666
Brooklyn, New York, United States
Pa0016 50664
Middletown, Ohio, United States
Pa0016 50680
Vandalia, Ohio, United States
Pa0016 50652
Duncansville, Pennsylvania, United States
Pa0016 50006
Wyomissing, Pennsylvania, United States
Pa0016 50001
Jackson, Tennessee, United States
Pa0016 50048
Baytown, Texas, United States
Pa0016 50687
Dallas, Texas, United States
Pa0016 50673
Fort Worth, Texas, United States
Pa0016 50657
Lubbock, Texas, United States
Pa0016 50655
Tomball, Texas, United States
Pa0016 50027
Seattle, Washington, United States
Pa0016 50061
Spokane Valley, Washington, United States
Pa0016 50674
Glendale, Wisconsin, United States
Pa0016 30002
Clayton, , Australia
Pa0016 30034
Footscray, , Australia
Pa0016 30033
Heidelberg, , Australia
Pa0016 30003
Maroochydore, , Australia
Pa0016 30032
Parramatta, , Australia
Pa0016 30009
Westmead, , Australia
Pa0016 40313
Pleven, , Bulgaria
Pa0016 40006
Plovdiv, , Bulgaria
Pa0016 40813
Plovdiv, , Bulgaria
Pa0016 40818
Plovdiv, , Bulgaria
Pa0016 40820
Plovdiv, , Bulgaria
Pa0016 40656
Rousse, , Bulgaria
Pa0016 40823
Rousse, , Bulgaria
Pa0016 40314
Sofia, , Bulgaria
Pa0016 40380
Sofia, , Bulgaria
Pa0016 40811
Sofia, , Bulgaria
Pa0016 40819
Sofia, , Bulgaria
Pa0016 50041
Québec, , Canada
Pa0016 50658
St. John's, , Canada
Pa0016 50044
Trois-Rivières, , Canada
Pa0016 40065
Brno, , Czechia
Pa0016 40062
Moravska Ostrava A Privoz, , Czechia
Pa0016 40802
Ostrava, , Czechia
Pa0016 40066
Prague, , Czechia
Pa0016 40801
Prague, , Czechia
Pa0016 40010
Uherské Hradiště, , Czechia
Pa0016 40012
Zlín, , Czechia
Pa0016 40073
Bad Nauheim, , Germany
Pa0016 40025
Berlin, , Germany
Pa0016 40515
Berlin, , Germany
Pa0016 40138
Bonn, , Germany
Pa0016 40808
Cologne, , Germany
Pa0016 40072
Freiburg im Breisgau, , Germany
Pa0016 40029
Hamburg, , Germany
Pa0016 40810
Herne, , Germany
Pa0016 40724
München, , Germany
Pa0016 40800
Ratingen, , Germany
Pa0016 40814
Tübingen, , Germany
Pa0016 40081
Budapest, , Hungary
Pa0016 40804
Budapest, , Hungary
Pa0016 40809
Hódmezővásárhely, , Hungary
Pa0016 40031
Szeged, , Hungary
Pa0016 20035
Bunkyō City, , Japan
Pa0016 20043
Itabashi-ku, , Japan
Pa0016 20045
Kita-gun, , Japan
Pa0016 20049
Kitakyushu, , Japan
Pa0016 20069
Meguro-ku, , Japan
Pa0016 20336
Mitaka-shi, , Japan
Pa0016 20033
Nagoya, , Japan
Pa0016 20041
Osaka, , Japan
Pa0016 20046
Osaka, , Japan
Pa0016 20031
Sapporo, , Japan
Pa0016 20335
Yokohama, , Japan
Pa0016 40789
Bialystok, , Poland
Pa0016 40791
Bialystok, , Poland
Pa0016 40824
Bialystok, , Poland
Pa0016 40119
Bydgoszcz, , Poland
Pa0016 40798
Bydgoszcz, , Poland
Pa0016 40038
Elblag, , Poland
Pa0016 40795
Katowice, , Poland
Pa0016 40092
Krakow, , Poland
Pa0016 40490
Krakow, , Poland
Pa0016 40502
Krakow, , Poland
Pa0016 40792
Krakow, , Poland
Pa0016 40037
Lublin, , Poland
Pa0016 40483
Nadarzyn, , Poland
Pa0016 40091
Nowa Sól, , Poland
Pa0016 40796
Olsztyn, , Poland
Pa0016 40794
Opole, , Poland
Pa0016 40044
Poznan, , Poland
Pa0016 40090
Poznan, , Poland
Pa0016 40807
Poznan, , Poland
Pa0016 40790
Sochaczew, , Poland
Pa0016 40788
Torun, , Poland
Pa0016 40094
Warsaw, , Poland
Pa0016 40394
Warsaw, , Poland
Pa0016 40539
Warsaw, , Poland
Pa0016 40604
Warsaw, , Poland
Pa0016 40793
Warsaw, , Poland
Pa0016 40797
Warsaw, , Poland
Pa0016 40043
Wroclaw, , Poland
Pa0016 40095
Wroclaw, , Poland
Pa0016 40805
Wroclaw, , Poland
Pa0016 40806
A Coruña, , Spain
Pa0016 40269
Bilbao, , Spain
Pa0016 40105
Córdoba, , Spain
Pa0016 40231
Madrid, , Spain
Pa0016 40102
Málaga, , Spain
Pa0016 40803
Sabadell, , Spain
Pa0016 40753
Santiago de Compostela, , Spain
Pa0016 40049
Seville, , Spain
Pa0016 40799
Seville, , Spain
Pa0016 40099
Vigo, , Spain
Pa0016 40833
Barnet, , United Kingdom
Pa0016 40829
Cambridge, , United Kingdom
Pa0016 40281
Leeds, , United Kingdom
Pa0016 40113
London, , United Kingdom
Pa0016 40827
Luton, , United Kingdom
Pa0016 40237
Manchester, , United Kingdom
Pa0016 40306
Newcastle upon Tyne, , United Kingdom
Pa0016 40812
Peterborough, , United Kingdom
Pa0016 40828
Reading, , United Kingdom
Pa0016 40108
Salford, , United Kingdom
Pa0016 40825
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-511738-11
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1306-6697
Identifier Type: OTHER
Identifier Source: secondary_id
PA0016
Identifier Type: -
Identifier Source: org_study_id